Ascendis Pharma A/S (ASND) CFO Smith bought 100 shares for $21.9K at $219.00
Insider transactions reported
Scott Thomas Smith (EVP & Chief Financial Officer at Ascendis Pharma A/S, ASND) reported that they bought 100 shares for $21.9K at $219.00 on Jun 2, 2026. After these transactions the filing shows 4,367 shares held directly.
- Reporting person
- Smith Scott Thomas
- Role
- EVP & Chief Financial Officer
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | Open-market purchase (P) | Ordinary Shares | +100 | $219.00 | $21.9K | 4,367 direct |
Holdings before and after
- Ordinary Shares: 4,267 to 4,367 direct
Transaction codes in this filing
- Open-market purchase:
- Code P marks a purchase in the open market or a private deal. The insider paid for these securities.
FAQ
What did Smith report in this ASND Form 4?
Scott Thomas Smith (EVP & Chief Financial Officer at Ascendis Pharma A/S, ASND) reported that they bought 100 shares for $21.9K at $219.00 on Jun 2, 2026. After these transactions the filing shows 4,367 shares held directly.
How many ASND shares does Smith hold after this filing?
The filing shows 4,367 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code P mean on an SEC Form 4?
Code P marks a purchase in the open market or a private deal. The insider paid for these securities.
Historical context for ASND
Across the 23 sessions after earlier ASND headlines, the stock closed higher 13 times and lower 10 times, with a median move of 2.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ASND | SPY |
|---|---|---|---|
| May 19, 2026 | Citigroup initiated coverage on Ascendis Pharma with a new price target | +0.1% | -0.7% |
| May 7, 2026 | Ascendis Pharma Reports First Quarter 2026 Financial Resultsand 1 other headline that session | +4.3% | -0.3% |
| May 1, 2026 | Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026 | -3.7% | +0.3% |
| Apr 22, 2026 | Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028 | -3.8% | +1.0% |
| Apr 20, 2026 | Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq | +0.4% | -0.2% |
| Apr 8, 2026 | Ascendis Pharma to List Ordinary Shares Directly on Nasdaqand 1 other headline that session | +5.8% | +2.5% |
Earlier insider filings at ASND
- Jun 1, 2026Director Bienaime Jean Jacques bought $111,562 worth of Ordinary Shares (500 units at $223.12), increasing direct ownership by 125% to 900 units (SEC Form 4)
- Jun 1, 2026EVP & Chief Financial Officer Smith Scott Thomas bought $55,830 worth of Ordinary Shares (250 units at $223.32), increasing direct ownership by 6% to 4,267 units (SEC Form 4)
- May 27, 2026Director Bienaime Jean Jacques bought $95,120 worth of Ordinary Shares (400 units at $237.80) (SEC Form 4)
- May 12, 2026Officer Jensen Flemming Steen sold $4,641,021 worth of Ordinary Shares (19,460 units at $238.49), closing all direct ownership in the company (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2015
Follow ASND and get a push notification the moment its next story breaks.